Multi-omics Characterization of Pancreatic Neuroendocrine Tumors and Carcinomas

Cancer of Pancreas Clinical Trial

— Camune  

Official title:

Multi-omics Characterization of Pancreatic Neuroendocrine Tumors and Carcinomas

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05234450
• Other study ID #: 7561
• Status: Recruiting
• Start date: December 1, 2021
• Est. completion date: June 30, 2022

Study information

• Verified date: January 2022
• Source: University Hospital, Strasbourg, France
• Contact: Gabriel MALOUF, MD, PhD
• Phone: 33 3 88 11 51 41
• Email: malouf.gabriel[@]chru-strasbourg.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In this work, the investigators count through the integrated multi-omics analysis to identify different tumor subgroups in pancreatic neuroendocrine tumors and carcinomas regardless of their grade and stage. To achieve this, they will resort to the use of next-generation sequencing approaches (RNAseq, then use of MCP Counter for the absolute quantification of the eight populations of immune cells in the tumor microenvironment), alterations in epigenetics with study of the methylome by MeDIP, ChIPseq, telomere (ALT) study, as well as correlation with peripheral blood neutrophil to lymphocyte ratio and immunohistochemistry data such as Ki67, p53, Rb, DAXX, ATRX, PDL1, immune cell labeling. This will be done on frozen or paraffin material. This work will provide a more complete biological picture of pancreatic neuroendocrine tumors and carcinomas.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: June 30, 2022
• Est. primary completion date: June 2022
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Adult patient (=18 years old)

• Subject with histologically confirmed tumor or neuroendocrine carcinoma of the pancreas

• Subject with tumors or neuroendocrine carcinoma of the pancreas regardless of the stage of the disease

• Supported at the University Hospitals of Strasbourg between 01/01/2008 and 01/09/2019

• Near therapeutic blood count available (less than 6 months)

• Availability of frozen and/or paraffin tumor material

• Patients who have already given their consent for their biological resources to be kept at the CRB or in the anatomopathology department of the HUS, and subsequently reused, as well as the anonymous data associated with them, for scientific research purposes.

Exclusion criteria:

• Opposition of the patient to participate in the study

• Diagnosis other than pancreatic neuroendocrine tumor

• Biological tissue from a patient who does not meet all the inclusion criteria

• Impossibility of giving informed information to the subject

• Patient under judicial protection En savoir plus sur ce texte sourceVous devez indiquer le texte source pour obtenir des informations supplémentaires Envoyer des commentaires Panneaux latéraux

Related Conditions & MeSH terms

• Cancer of Pancreas
• Carcinoma
• Neuroendocrine Tumors
• Pancreatic Neoplasms

Locations

Country	Name	City	State
France	Service d'Oncologie - CHU de Strasbourg - France	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Establishment of the number of tumor subgroups by integrating data from all multi-omics analyses		1 month